House
Create account
Drug reference directory
Drug reference

zanubrutinib

BTK inhibitor · Antineoplastic agent

BTK inhibitorAntineoplastic agent
CDSCO approved
EXCRETION
—
not curated
INTERACTIONS
12 major
SEVERE in our sources
PREGNANCY
D
FDA category + note
Top interactionssee all 12 →
  • AbciximabSevereDatabaseDDInter
  • AcalabrutinibSevereDatabaseDDInter
  • AdalimumabSevereDatabaseDDInter
  • AlteplaseSevereDatabaseDDInter

Mechanism

Zanubrutinib is an orally bioavailable inhibitor of BTK that forms a covalent bond with a cysteine residue in the BTK active site and shows a higher selectivity for BTK versus other kinases (e.g., ITK, EGFR), resulting in less off-target effects.

Indications

MCL who have received at least one prior therapy

Pharmacokinetics

Duration
BTK occupancy in peripheral mononuclear cells maintained at 100% over 24 h and at 94% to 100% in lymph nodes
Half-life
2 to 4 h (elimination)

Side effects

Common
lower rates of atrial fibrillation compared to ibrutinib
Serious
  • skin cancers (secondary primary malignancies)
  • hemorrhage
  • arrhythmias

Pregnancy & lactation

Pregnancy

D

Drug interactions

Abciximab
Severe
Database

Drug interaction classified as: synergy

Source: DDInter

Acalabrutinib
Severe
Database

Drug interaction classified as: synergy

Source: DDInter

Adalimumab
Severe
Database

Drug interaction classified as: synergy

Source: DDInter

Alteplase
Severe
Database

Drug interaction classified as: synergy

Source: DDInter

Amprenavir
Severe
Database

Drug interaction classified as: metabolism

Source: DDInter

Anagrelide
Severe
Database

Drug interaction classified as: synergy

Source: DDInter

Anisindione
Severe
Database

Drug interaction classified as: synergy

Source: DDInter

Anistreplase
Severe
Database

Drug interaction classified as: synergy

Source: DDInter

Antithrombin Alfa
Severe
Database

Drug interaction classified as: synergy

Source: DDInter

Antithrombin Iii Human
Severe
Database

Drug interaction classified as: synergy

Source: DDInter

Apalutamide
Severe
Database

Drug interaction classified as: metabolism

Source: DDInter

Apixaban
Severe
Database

Drug interaction classified as: synergy

Source: DDInter

Related guidelines

Heart failure in diabetes
RSSDI · Cardiology · 2023
Hypertension in adults
ICMR · Cardiology · 2019
Hypertrophic cardiomyopathy
ESC · Cardiology · 2026
Diabetes management in chronic kidney disease
KDIGO · Nephrology · 2022
Acute liver failure
ICMR · Gastroenterology · 2022

Other BTK inhibitor drugs

acalabrutinib
0 brands

Ask House about zanubrutinib

Continue into a citation-backed clinical answer with the drug context already attached.

Open in workspaceAsk House about this drug

Textbook-sourced·Sources: Goodman & Gilman 14e, Harrison 22e·Updated: 2026-05-10